October 26, 2009

Virogen Inc, symbol VRGN.pk has completed the spin off of its vaccine business into a private entity. The original founders and private investors of Virogen have agreed to acquire the business in exchange for certain funding commitments and debt exchange. The private investors feel strongly in the opportunity available and will continue to execute the existing business model. In executing this transaction the company recognized the long term risks to shareholders in launching a new biological vaccine in the world markets, investments required, and the challenges involved in acquiring revenue streams in the short and midterm which in this environment is not well suited the needs and requirements of a public company. . In order to maximize shareholder value VRGN has become a holding company that has acquired the rights to a license and joint venture with Evotech Technologies. Under terms of the agreement VRGN will share on a equal basis all revenues derived from the marketing and sales of a suite of proprietary tools developed by Tiger Team Technologies to address the very pressing issues of network security in China. In addition VRGN will receive a 30% equity stake in a new entity to be formed for this purpose. Evotech Technologies has a long history of success with its portfolio companies in China and the company looks forward to continued success with the new joint venture in the Asian market place. In moving forward with this transaction the company looks forward to enhancing shareholder value with this asset base and anticipated revenue streams in the near to mid term.

0 Comments

MINNEAPOLIS, MN--(MARKET WIRE)--May 5, 2009 -- Virogen, Inc. (Other OTC:VRGN.PK - News), the developer and patent holder of a revolutionary vaccine to combat the deadly Newcastle Disease that kills chickens worldwide, has received escalating inquiries for its unique Innovo Newcastle Vaccine by governments, producers, and distributors across the globe as a result of the increased demand for poultry due to the unfortunate Swine Flu outbreak.

Pork imports have been curtailed by 12 countries to date and this trend is expected to increase as countries worldwide move to protect their citizens and take further precautions against the spread of the disease. Taking a very aggressive and dramatic step, the Government of Egypt has ordered the slaughter of the entire swine population throughout the country.

As a result of these and other cautionary measures, it is anticipated, if not inevitable, that for the near term 6-12 months poultry consumption and demand will spike dramatically. This very well could create a long term change in terms of consumption worldwide as pork products could be permanently curtailed by populations everywhere in spite of dubious attempts by the World Health Organization to change the name Swine Flu to influenza A(H1N1) to avoid suggestions that eating pork products could carry a risk of infection.

As the demand for poultry increases, the possibilities for outbreaks of Newcastle Disease also increase, thus enhancing the need for Virogen's products and services. Virogen has already experienced an increase in inquiries for its flagship Innovo Newcastle Vaccine by governments, producers, and distributors across the globe. In order to fulfill the anticipated need to protect flocks around the world, the company is moving rapidly on all fronts to accommodate these recent changes in demand and market conditions. Preliminary indications are that government officials worldwide are willing to fast track the approval process for Virogen's poultry vaccines. With time lines shortened, Virogen's market opportunities are almost certain to be accelerated and significantly enhanced.

Investors and potential investors are invited to call Paul Hogan, CEO Virogen, Inc. at (415) 251-1141 to request a copy of the company's complete business plan.

Or, for Investors Relations and more information contact: Guy Vinci, VUI Consulting at 386-218-5929

Forward-Looking Statements:

0 Comments

MINNEAPOLIS, MN--(MARKET WIRE)--Apr 20, 2009 -- Virogen, Inc. (Other OTC:VRGN.PK - News), the developer and patent holder of a revolutionary vaccine to combat the deadly Newcastle disease that kills chickens worldwide, is making public the following letter that CEO Paul Hogan has written to the company's shareholders.






Dear Shareholders:

First I would like to extend my thanks to all those who are participating in the support and success of the company. For all of you, as well as those new to the company, I would like to offer the following update:

Virogen received the manufacturing and export license approval under European Union regulatory standards at the end of July 2008. Once the license was granted, the company aggressively began pursuing registrations and contracts with distributors worldwide. To date, the company has signed contracts with two major distributors in the Middle East and in Asia, and these existing contracts are expected to be operational by July 1, 2009.

Virogen presently has $400,000 in purchase orders from these distributors and is in the final stages of obtaining registrations in the countries where these distributors are doing business. This process normally takes two years, but the company has been placed on the fast track due to the government's recognition of the urgent need and producer support for Virogen's Innovo Newcastle Vaccine.

At this time contracts are being reviewed by several other distributors and registrations are being pursued in Thailand, Indonesia, India, Brazil, Russia, and China to name just a few of the markets being cultivated simultaneously. By the second quarter of 2010, it is anticipated that the aforementioned markets and many others will be utilizing Virogen's vaccine.

Finally the company is implementing an aggressive R&D program to develop new products it can introduce to the marketplace in 2010. Beginning in the second half of 2008 and continuing through the first quarter of 2009, Virogen has successfully executed a transition from a purely R&D company to a commercial enterprise. The company looks forward to continued success as it pursues this strategy and successfully executes its business model worldwide.



Respectfully,
Paul Hogan
Chief Executive Officer
Virogen Inc.
Investors and potential investors are invited to call Paul Hogan, CEO Virogen, Inc. at (415) 367-4058 to request a copy of the company's complete business plan

0 Comments

Effective: 02/26/2009

ISSUE: VIROGEN, INC. COMMON STOCK (92823W200) (VRGN.PK)

Shares Authorized: 100.000.000
Holders
Stated Outstandina: o
LESS: Shares Outstandina: ( 1.274.270) Total 302
Shares RESERVED: ( 0) Active 264

Shares available to issue: 98.725.730i
Free Trading Shares: 450,650i

Cert Outstandina: 1.227.014i
Book Outstanding: 47,256i

Report Run On 2/26/2009 At 3:20pm By MATTHEW LUGINBUEHL

0 Comments

MINNEAPOLIS, MN--(MARKET WIRE)--Mar 31, 2009 -- Virogen, Inc. (Other OTC:VRGN.PK - News), the developer and patent holder of a revolutionary vaccine to combat Newcastle disease, a deadly disease that kills chickens worldwide, has been notified by its Middle Eastern distributor that its flagship vaccine Innovo immune has been approved by the Egyptian Registration Committee. This is a milestone for the company because Egypt has the one of the most stringent requirements for approval of biological vaccines, and immediately upon receipt of the formal license, Virogen will be able to fill existing purchase orders of over $200,000 from its distributor in Egypt. Virogen is also on the verge of finalizing its registration in Pakistan, where a $200,000 purchase order is ready to be filled.

The only criteria now remaining is receipt of a registration number and labeling instructions designated by the Egyptian Committee. Once these are issued, the company will immediately begin manufacturing and importing the vaccine into Egypt. That will also open the door for Microbitech, Virogen's distributor, to fulfill existing contracts with the two largest poultry producers in the Middle East, enabling them to immediately fill over $200,000 in orders that are already in place.

While poultry vaccines are now available in the form of a spray or nasal inhalant, the product developed by Virogen is 2,000 times more potent than those now on the market. It is injected directly into the chicken embryo and provides immunity up to ten weeks, with the average time to market being six weeks. Competitively, it is far cheaper to produce, more effective, and much less expensive to the purchaser than conventional vaccines.

Newcastle is a deadly disease which can decimate entire flocks should an outbreak occur. Fully 85% of the worldwide market resides outside of the United States. Foreign markets are experiencing rapid growth as protein consumption abroad is rising at a far more rapid rate than in the US. Therefore, the company has made the strategic decision to concentrate its resources on these world markets.

Statement by Paul Hogan, CEO

Paul Hogan, CEO of Virogen, Inc. notes, "Every production bird in the world is required to be vaccinated, and since Virogen's vaccine is the only Innovo patent-protected product on the market, the company anticipates it will capture this exclusive market for several years. With approximately 45 billion birds being produced annually outside of the United States and consumption growing by close to 30% per annum and expected to increase exponentially, one can anticipate the revenue opportunity for this vaccine is in the tens of millions over the product life cycle."

Forward-Looking Statements:

This press release contains statements, which may constitute "forward-looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of Virogen, Inc. and members of its management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. The Company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.

Contact:
For More Information, contact:
Paul Hogan
CEO
Virogen, Inc.
(415) 367-4058

Guy Vinci
VUI Consulting
386-218-5929

0 Comments